IDENTIFYING CHILDREN WITH SUBCLINICAL NEUROCOGNITIVE DECLINE AND SUSCEPTIBILITY TO OXIDATIVE DAMAGE DURING THE EARLY MONTHS OF THERAPY FOR ALL